Abrasis Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 4 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 0.50 M
- Revenue Growth %
- Profit Growth -1.34%
- Ebitda -1.34%
- Net Worth -54.57%
- Total Assets 487.20%
About Abrasis Lifesciences
Abrasis Lifesciences Private Limited (ALPL) is a Private Limited Indian Non-Government Company incorporated in India on 15 September 2020 (Four years and four months 24 days old ). Its registered office is in Thiruvananthapuram, Kerala, India.
The Company is engaged in the Non-Profit Organizations Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.50 M.
Ramesh Vasantha and Suchithra Remani serve as directors at the Company.
Company Details
-
Location
Thiruvananthapuram, Kerala, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U85320KL2020PTC064402
-
Company No.
064402
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
15 Sep 2020
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at Abrasis Lifesciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramesh Vasantha
|
Director | 15-Sep-2020 | Current |
|
Suchithra Remani
|
Additional Director | 14-Nov-2023 | Current |
Financial Performance of Abrasis Lifesciences.
Abrasis Lifesciences Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a slight decrease in profitability, with a 1.34% decrease in profit. The company's net worth observed a substantial decline by a decrease of 54.57%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Abrasis Lifesciences?
Unlock access to Abrasis Lifesciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹0.50 M
₹0
Charges Breakdown by Lending Institutions
- Canara Bank : 0.05 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 02 Nov 2022 | Canara Bank | ₹0.50 M | Open |
How Many Employees Work at Abrasis Lifesciences?
Unlock and access historical data on people associated with Abrasis Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Abrasis Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Abrasis Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
